These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 19434630)

  • 1. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.
    Prichard MN
    Rev Med Virol; 2009 Jul; 19(4):215-29. PubMed ID: 19434630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress.
    Hamirally S; Kamil JP; Ndassa-Colday YM; Lin AJ; Jahng WJ; Baek MC; Noton S; Silva LA; Simpson-Holley M; Knipe DM; Golan DE; Marto JA; Coen DM
    PLoS Pathog; 2009 Jan; 5(1):e1000275. PubMed ID: 19165338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Cytomegalovirus Can Procure Deoxyribonucleotides for Viral DNA Replication in the Absence of Retinoblastoma Protein Phosphorylation.
    Kuny CV; Kalejta RF
    J Virol; 2016 Oct; 90(19):8634-43. PubMed ID: 27440891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complex.
    Sharma M; Bender BJ; Kamil JP; Lye MF; Pesola JM; Reim NI; Hogle JM; Coen DM
    J Virol; 2015 Jan; 89(1):523-34. PubMed ID: 25339763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress.
    Krosky PM; Baek MC; Coen DM
    J Virol; 2003 Jan; 77(2):905-14. PubMed ID: 12502806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
    Chou S; Watters M; Sinha R; Kleiboeker S
    Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of retinoblastoma protein does not overcome the requirement for human cytomegalovirus UL97 in lamina disruption and nuclear egress.
    Reim NI; Kamil JP; Wang D; Lin A; Sharma M; Ericsson M; Pesola JM; Golan DE; Coen DM
    J Virol; 2013 May; 87(9):5019-27. PubMed ID: 23427156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
    Chou S; Hakki M; Villano S
    Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
    Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
    J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
    Chou S; Ercolani RJ; Marousek G; Bowlin TL
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir.
    Gill RB; Frederick SL; Hartline CB; Chou S; Prichard MN
    Virol J; 2009 Jan; 6():9. PubMed ID: 19159461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An epistatic relationship between the viral protein kinase UL97 and the UL133-UL138 latency locus during the human cytomegalovirus lytic cycle.
    Li G; Rak M; Nguyen CC; Umashankar M; Goodrum FD; Kamil JP
    J Virol; 2014 Jun; 88(11):6047-60. PubMed ID: 24623439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
    James SH; Hartline CB; Harden EA; Driebe EM; Schupp JM; Engelthaler DM; Keim PS; Bowlin TL; Kern ER; Prichard MN
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4682-91. PubMed ID: 21788463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ULb' region of the human cytomegalovirus genome confers an increased requirement for the viral protein kinase UL97.
    Wang D; Li G; Schauflinger M; Nguyen CC; Hall ED; Yurochko AD; von Einem J; Kamil JP
    J Virol; 2013 Jun; 87(11):6359-76. PubMed ID: 23536674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
    Chou S
    Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
    Chou S; Wechel LC; Marousek GI
    J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.
    McGregor A; Choi KY; Cui X; McVoy MA; Schleiss MR
    Antiviral Res; 2008 Jun; 78(3):250-9. PubMed ID: 18325607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
    Chou S; Marousek GI
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.